Category: Money tips Release Date: 2007-07-15
Source: Wuhan New Rand Authors: Zhu Handong
Muller to enhance corporate value
With the Shanghai and Shenzhen stock market short of change in the split share structure reform has been formally drawing to a close, a number of the company's "cardinal" will also be gradually lifted. Well-floating era, capital markets, mergers and acquisitions will be a growing wonderful story. Many first two major shareholders of listed companies in order to compete for control of the company's Costly, raised placards so the event also occur frequently. The deepening of the participants under the market value of these companies are also synchronized to upgrade. Wuhan Jianmin (600,976) is also a major shareholder in a scramble for the "fragrant steamed bun", the worst in the widespread speculation.
Jointly par Nanjing Medical Kyushu Pass
Wuhan Jianmin is a national key high-tech enterprise, the National Chinese medicine production base in pediatric medicine, national key enterprise of Chinese medicine. The company's predecessor was the oldest of the four traditional Chinese medicine in China, one of Ye Kaitai Shoppes at pharmacies, dating back nearly four centuries of history, now has more than ten subsidiary companies, the annual production capacity of nearly one billion yuan. At present, Wuhan Jianmin has been successfully developed and developed in order to Longmu Zhuanggu particles, Jian-Min throat piece, represented by a series of products.
45% owned subsidiary company of Wuhan Jianmin Pharmaceutical Co., Ltd. has a core technology Dapeng country a class of traditional Chinese medicine drug ICCB industrialization has achieved significant progress, the company ICCB's production has begun to take shape. Jian-Min ICCB Dapeng has all the intellectual property rights, patents and industrial equipment, patents, is China's ICCB sole manufacturer and supplier. Companies to invest 160 million yuan Taiwanese investment zone in Wuhan Science and Technology Industrial Park, built 7 GMP production workshops, production and sales of 52 kinds of proprietary Chinese medicines. ICCB company already has an annual capacity of 5000 kilograms, producing more than 10 varieties of formulations products, products have been exported to South Korea and other places started. ICCB up to 10 billion market prospects for the development of Mirs Jian-Min brings a broad space for development, ICCB, Wuhan Jianmin will become an important future profit growth.
And Wuhan Kin crazy people and had a moment in the market of Nanjing Medical has a strong comparable medicine in Nanjing today, another new high, spurred by price, Wuhan Jianmin also has an excellent market opportunity.
Nanjing Medical reason for a soaring, it is because the company has a multi-regional, covering a population of 200 million market network platform and the modern pharmaceutical logistics system, and benefit from medical trusteeship system. However, Nanjing Medical pharmaceutical business enterprises at the national median sales of 100 was just a fourth place, Wuhan health people and ranked Sinopharm and Shanghai Pharmaceutical Group, the third of the Kyushu-pass extremely close working relationship.
Kyushu-pass was established in 2000, with annual sales from the year of 4 billion, has skyrocketed in 2004 to 84 billion, is expected to exceed 14 billion yuan this year's level. Wuhan Jianmin invested 30.6 million yuan holding 51% of Shandong medicine mountain pass, and Beijing is the reason of Kyushu toyoshina city founded pharmaceutical companies. Jian Tong, Wuhan people and Kyushu, in cooperation so that the first inter-regional Wuhan Jianmin Pharmaceutical business investment, business profits have greater protection, and into the pharmaceutical business occupy a good position to take quick batch mode and so help improve the pharmaceutical business operate more efficiently. According to estimates, Shandong Yakuyama main business revenue in 2006 of up to one billion yuan.
In addition, since the beginning of September 2005, China General Technology (Group) owned subsidiary of General Logistics as a common investment and persons acting in concert raised placards Wuhan Jianmin. Continued holdings in General in Wuhan Jianmin, the company's largest shareholder of Holley Group has also taken action. This year, April 14, Holley Group invested 131.2262 million yuan, total acquisition of state-owned asset management companies in Wuhan in Wuhan Jianmin total of 1411.03 million shares owned by state-owned shares. Raised placards through this war, the company's popularity surge, and thus stock prices steadily increase.
The amount of the outbreak with the limit-price
K-line from the weeks of view, the listed Wuhan Jianmin, after more than a year down to build a mega success of "V" a turning point. In May last year, after the stock movements so smooth, the stock shocks all the way up until after the share reform Fang Cai entered a new cycle of adjustments. It seems from the recent trend, a new "V"-type reversal in progress, stock drop in the overall recovery of lost territory, the Tian Quan entered a new phase. Ex-stock reform in the gap, attracted by Wuhan Jianmin up extremely strong impulse. From the Japanese portfolio of K-line appears, the Unit completed its share reform after the re-distribution of new chips, the stock in recent weeks has shown a clear sign of strengthening. Relying on several moving averages, the stock has not even received six-yang, smooth out short-term moving average entanglement, begun to enter the speed up process. The 60-day moving average is also in place to adjust the last two trading days, coupled with the bottom of the constant turnover of larger co-limit-a great chance of an outbreak.
